Implante intravítreo de dexametasona como terapéutica del edema macular persistente en la retinocoroidopatía de Birdshot

Zea, P. Rivera de; García-Ben, A.; Parshotam, N. Rachwani; García-Campos, J.M.

doi:10.1016/j.oftal.2015.10.012

Cited by 3 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ozurdex releases dexamethasone in a biphasic manner over 6 months, with higher concentrations released for the first 6 weeks. Although there are no clinical trials specifically evaluating the use of Ozurdex in BCR, there are individual case reports of the use of Ozurdex in BCR [ 87 – 89 ], and it is worth noting that patients with BCR are often significant contributors to studies which support the use of Ozurdex in uveitis. For example in their retrospective cohort studies of Ozurdex in posterior segment uveitis, Zarranz-Ventura et al reported that 12 of 82 patients enrolled had BCR, and Pelegrin reported 7 of 42 patients with BCR [ 90 , 91 ].…”

Section: Introductionmentioning

confidence: 99%

Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment

Minos

Barry

Southworth

et al. 2016

Orphanet J Rare Dis

101

View full text Add to dashboard Cite

Birdshot chorioretinopathy (BCR) is a rare form of chronic, bilateral, posterior uveitis with a distinctive clinical phenotype, and a strong association with HLA-A29. It predominantly affects people in middle age. Given its rarity, patients often encounter delays in diagnosis leading to delays in adequate treatment, and thus risking significant visual loss. Recent advances have helped increase our understanding of the underlying autoimmune mechanisms involved in disease pathogenesis, and new diagnostic approaches such as multimodality imaging have improved our ability to both diagnose and monitor disease activity. Whilst traditional immunosuppressants may be effective in BCR, increased understanding of immune pathways is enabling development of newer treatment modalities, offering the potential for targeted modulation of immune mediators. In this review, we will discuss current understanding of BCR and explore recent developments in diagnosis, monitoring and treatment of this disease.Synonyms for BCR: Birdshot chorioretinopathy, Birdshot retinochoroiditis, Birdshot retino-choroidopathy, Vitiliginous choroiditis.Orphanet number: ORPHA179OMIM: 605808.

show abstract

Section: Introductionmentioning

confidence: 99%

Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment

Minos

Barry

Southworth

et al. 2016

Orphanet J Rare Dis

101

View full text Add to dashboard Cite

show abstract

Birdshot retinochoroidopathy: pathophysiology, diagnosis and treatment

Small

Ferrara

Schmidt

et al. 2017

Expert Opinion on Orphan Drugs

View full text Add to dashboard Cite

Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis

Papasavvas¹,

Tuğal-Tutkun

Herbort³

2022

Pharmaceuticals

View full text Add to dashboard Cite

Background: Non-infectious choroiditis comprises immune-mediated diseases resulting from diverse pathophysiological mechanisms. These conditions are sub-divided into two main groups, (1) diseases of the choriocapillaris and (2) diseases of the choroidal stroma. The purpose of this study is to expose the pathophysiology of the most common diseases of both these groups and recommend the optimal immunomodulatory/immunosuppressive therapy of each analyzed condition based on literature data and data from our own centers. Material and Methods: Narrative review. In the group of choriocapillaritis entities or primary inflammatory choriocapillaropathies (PICCPs) including multiple evanescent white dot syndrome (MEWDS), acute posterior multifocal placoid pigment epitheliopathy (APMPPE), idiopathic multifocal choroiditis (MFC) and serpiginous choroiditis (SC), as well as secondary choriocapillaritides including acute syphilitic posterior multifocal placoid chorioretinitis (ASPMPC) and tuberculosis-related SC (TB-SC), were analyzed. In the group of stromal choroidites, HLA-A29 birdshot retinochoroiditis (BRC) and Vogt-Koyanagi-Harada (VKH) disease were included. For each entity a literature search, in the PubMed database, on treatment was performed and analyzed and the therapeutic attitudes of our own centers were presented. Conclusion: Management of immune-mediated choroiditis implies vigorous immunosuppressive therapy given in a prompt and prolonged fashion in most of these entities.

show abstract

Implante intravítreo de dexametasona como terapéutica del edema macular persistente en la retinocoroidopatía de Birdshot

Cited by 3 publications

References 11 publications

Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment

Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment

Birdshot retinochoroidopathy: pathophysiology, diagnosis and treatment

Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis

Contact Info

Product

Resources

About